most abundant leukocytes in Human blood, but it is not clear whether neutrophils exert an important role in the pathogenesis of organ tissue damage in SLE.

Methods We used lupus-prone mouse model and model of lupus serum-induced tissue inflammation in mouse to investigate the role of neutrophils in the organ damage of SLE.

Results We found that there was a little neutrophil infiltration in the inflammatory sites of skin, liver, brain and joint in lupus-prone mice. We also found that there was also little neutrophil infiltration in the site of skin inflammation induced by lupus serum in normal mouse. The severity of skin inflammation induced by lupus serum was not significantly decreased in mice with neutrophil depletion compared to ones without neutrophil depletion. But we found that neutrophils were actually involved in tissue injury induced by lupus IgG. Further studies showed that lupus IgG stimulated and activated neutrophils, and cause the death of neutrophils. Studies also confirmed that Fas plays an important role in neutrophils apoptosis.

Conclusions Our study indicates that neutrophils participate in the early stage of lupus organ damage, and then they died through activation-mediated apoptosis. These findings promote the understanding of the role of neutrophils in the tissue injury with SLE.

340

TLR8 ACTIVATION IN NEUTROPHILS IMPAIRS IMMUNE COMPLEX PHAGOCYTOSIS THROUGH FURIN-DEPENDENT SHEDDING OF FCGRIIA

K Elkon*, S Arve, J Ledbetter, C Lood. University of Washington, Medicine, Seattle, USA

10.1136/lupus-2017-000215.340

Background and aims Neutrophils play a crucial role in host defense through mechanisms including phagocytosis and formation of neutrophil extracellular traps (NETs), a recently identified neutrophil cell death process in which DNA is extruded together with cytoplasmic and granular content to trap and eliminate extracellular pathogens. Although beneficial from a host-pathogen perspective, exaggerated neutrophil activation has been linked to autoimmunity, in particular the rheumatic disease systemic lupus erythematosus (SLE) where nucleic acid-containing immune complexes (IC) drive inflammation. Toll-like receptor (TLR) agonists, such as nucleic acids, are important components of pathogens, enabling enhanced phagocytosis by macrophages and dendritic cells, but the role of TLR signalling in processing of SLE ICs and downstream inflammatory neutrophil effector functions is not known.

Methods Standard Methods.

Results We observed that both FcgR- and TLR8-engagement were required for induction of NETosis, whereas TLR8 activation, through the RNA component of the ICs, suppressed further IC-mediated phagocytosis. Mechanistically, TLR8 ligation induced PI3K-dependent ROS generation through NADPH oxidase, and subsequent furin-dependent proteolytic cleavage of the N-terminal part of FcgRIIA shifting neutrophils away from phagocytosis of ICs toward NETosis. TLR8 activated neutrophils promoted cleavage of FcgRIIA also on plasmacytoid dendritic cells and monocytes resulting in impaired overall clearance of ICs and increased complement C5a generation. Importantly, *ex vivo* derived activated neutrophils from SLE patients demonstrated a similar cleavage of FcgRIIA

that was correlated with markers of disease activity as well as complement activation.

Conclusions Therapeutic approaches aimed at blocking TLR8 activation would be predicted to increase phagocytosis of circulating ICs while disarming their inflammatory potential.

341

CD11B REGULATES INFLAMMATION, AUTOIMMUNITY AND ASSOCIATED PATHOLOGY IN A MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS

T Gottschalk*, E Tsantikos, M.L. Hibbs. Monash University, Department of Immunology and Pathology, Melbourne, Australia

10.1136/lupus-2017-000215.341

Background and aims Systemic Lupus Erythematosus (SLE) is a highly complex, heterogeneous autoimmune disease characterised by circulating self-reactive antibodies that deposit in tissues including skin, kidneys and brain, alongside a chronic inflammatory response that leads to progressive tissue damage and impaired function. Genome-wide association studies have identified a number of receptors and signal transduction molecules specific for the immune system that predispose to the development of SLE. A loss-of-function single nucleotide polymorphism (SNP) in the Itgam gene encoding CD11b (rs1143679) has been identified which associates with an increased incidence of SLE, implicating CD11b as a protective factor against disease development. To understand the role that CD11b plays in controlling autoimmune disease, we crossed CD11b deficient mice (CD11b-/-) with Lyn deficient (Lyn^{-/-}) mice, a well-studied, robust model of human SLE.

Methods Double knockout Lyn--CD11b-- mice were analysed over time for development of autoimmune disease and inflammation.

Results While CD11b^{-/-} mice presented with mild splenomegaly and lymphadenopathy, immune cell compartments were unchanged and pathogenic IgG anti-dsDNA autoantibody titres and glomerulonephritis were undetected suggesting that CD11b deficiency alone is insufficient to drive autoimmune disease. Conversely, deficiency of CD11b on the Lyn-deficient autoimmune-prone background exacerbated disease, driving splenomegaly and lymphadenopathy, extramedullary haematopoiesis, autoantibody production and glomerulonephritis, which heavily impacted survival.

Conclusions These findings confirm that CD11b is an autoimmune susceptibility gene that when mutated can exacerbate the severity of disease on a susceptible genetic background. This work highlights an important role for CD11b in regulating and controlling the progression of inflammation and autoimmune disease.

342

NEW POSSIBILITIES OF HUMAN COMPLEMENT SYSTEM IN DIAGNOSTICS AND ANALYSES OF AUTOIMMUNE DISEASES

¹V Lakhtin*, ²M Naxthn, ¹S Andina, ¹S Afanasiev, ¹O Logunov, ¹V Aleshkin. ¹G.N. Gabrichevsky research Institute for Epidemiology and Microbiology, Department of Biotechnology, Moscow, Russia; ²G.N. Gabrichevsky research Institute for Epidemiology and Microbiology, Department of Biotechology, Moscow, Russia

10.1136/lupus-2017-000215.342

Background and aims The aim was to summarise own data on the human complement system involving cofunctioning

A150 LUPUS 2017;4(Suppl 1):A1–A227

complement and other innate protective systems against infectious and autoimmunity diseases.

Methods Components of the patient serum complement (CPSC) were registered by immunochemical methods in microplates (variants of functional analyses of isotypes C4A and C4B, and C1-inhibitor upon supramolecular assembling on well bottom) and on the blot (preliminary isoelectrophoresis of sera in the plate of polyacrylamide gel). Rabbit and goat polyclonal antibodies against purified CPSC were used. Activity of antibodies-peroxidase conjugates bound to CPSC was detected in the presence of TMB (microplate) or chemiluminescent substrate in a real time [BioChemi System (UVP)].

Results 1.Sera of patients having autoimmune diseases were characterised on the blot by appearance of aggregated C4B and C4A within pI 4,0–4,7 compared to less acidic free isotypes. Functional status of isotypes was confirmed in microplate. Absolute amounts of isotypes and their subisotypes as well as ratio of isotypes characterised prognostic-diagnostic patient groups of diseases (SLE, antiphospholipid syndrome, rheumatoid arthritis). Appearance and relative intensities of the system of aggregated isotypes and subisotypes of C4 indicated the presence of disease, its initiation, reached phase of disease and disease character. 2.Similar localization on the blot for the complex C4B and C1-inhibitor of patients was registered.

Conclusions Results indicate possible cofunctioning C4B and C1-inhibitor in protection complement network upon development of autoimmune diseases. New mechanisms of cascade protection involving new combinations of CPSC may be revealed. Results open new practical possibilities in diagnostics of early, progressive and chronic autoimmune diseases.

343

COMPLEMENT LECTIN SYSTEM COFUNCTIONS TO OTHER PROTECTIVE PRO-TEIN SYSTEMS INVOLVING RELATIONSHIPS BETWEEN LECTINS AND GLYCOCONJUGATES AGAINST AUTOIMMUNE AND INFECTIOUS DISEASES

M Lakhtin, V Lakhtin*, S Andina, S Afanasiev, V Aleshkin. G.N. Gabrichevsky research Institute for Epidemiology and Microbiology, Medical Biotechnology, Moscow, Russia

10.1136/lupus-2017-000215.343

Background and aims Innate protection recognising systems of human organism are important and perspective in respect of investigation autoimmune and infectious diseases. The aim was to evaluate lectin system (LS) of complement and its importance for innate interactome against infectious and autoimmune diseases.

Methods Patient complement components (PCC) of sera were estimated by immunochemical methods in microplates (hybrid plate for C4A and C4B functionality testing) and on the blot (for PCC separated by isoelectrophoresis). Peroxidase activity was detected using TMB or chemiluminescent substrate (for blot, *BioChemi System*, UVP).

Results Additional glycoconjugates(GC)-binding PCC were registered.

C1-inh revealed affinity to heparin. Patient (SLE, antiphospholipid syndrome, rheumatoid artritis) subisotypes of C4B (up to 5) and C4A (up to 7) were observed as aggregated forms together with GC.

Conclusions 1. Extended complement LS includes MBL, Factor H, C1-inh, CR1, CR2, CR3, C3, C4B, others. 2. Complement serve as a universal communicator among protective systems involving their LS—GC communications. 3. Complement (as mostly advanced innate protection system) possesses structure-function principles prognostic for any innate recognition systems. 4. There is superLS network in organism. Probiotic LS is important cofunctioning part of it. 5. The data support idea that any protection protein system partially functions involving LS—GC recognition (also for antibodies recognised by Fc-receptors as LS). 6. New prognostic-diagnostic possibilities in investigation of autoimmune and infectious diseases are opened using interactome LS—GC network.

Innate immunity

344

LINKING MACROPHAGE MIGRATION INHIBITORY FACTOR AND NLRP3 IN THE PATHOGENESIS OF IL-1 DEPENDENT INFLAMMATORY DISORDERS

¹T Lang*, ¹J Lee, ¹A Pinar, ¹H Fan, ²A Mansell, ¹E Morand, ¹J Harris. ¹Monash University, School of Clinical Sciences at Monash Health, Clayton, Australia; ²Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia

10.1136/lupus-2017-000215.344

Background and Aims Macrophage migration inhibitory factor (MIF) is a mediator of innate immunity and is implicated in the pathogenesis of numerous autoinflammatory disorders. Clinical studies have shown correlations between elevated levels of IL-1 β and MIF in serum with disease outcomes of patients with autoimmune disorders. To date, it is unclear whether MIF specifically regulates the expression and secretion of IL-1 family cytokines. Therefore, we aim to characterise mechanisms by which MIF may modulate the secretion of IL-1 family cytokines.

Methods The biological activity of MIF in murine bone marrow derived macrophages (BMDM) was inhibited using a small molecule inhibitor, COR123625. Concurrently, BMDM derived from Mif $^{\prime\prime}$ mice were employed to evaluate the effects of MIF depletion on regulation of IL-1 family cytokines. mRNA expression was analysed by qRTPCR. Protein expression and secretion of IL-1 α , IL-1 β and IL-18 was assessed by western blot and ELISA.

Results We show that depletion of MIF in macrophages significantly reduced IL-1 cytokine release specifically in response to NLRP3 stimuli, but has no effect on the secretion of TNF- α and IL-6. Moreover, diminished IL-1 responses were independent of production of pro-IL-1 β . Instead, MIF depletion specifically inhibits NLRP3-mediated IL-1 responses as levels were unaffected following activation of AIM2 or NLRC4 inflammasomes.

Conclusions Our findings reveal a novel role for MIF in the modulation of IL-1-dependent inflammatory responses, linking MIF directly to NLRP3 inflammasome activation. This study for the first time implicates a specific role for MIF in the release of IL-1 family cytokines and highlights the potential of targeting MIF in IL-1-dependent pathologies.

LUPUS 2017;**4**(Suppl 1):A1–A227